Tygacil (tigecycline) injection — CareFirst (Caremark)
Complicated intra-abdominal infections caused by susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus group, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros in adults age ≥ 18 years
Initial criteria
- Tygacil is not indicated for the treatment of diabetic foot infections
- Tygacil is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tygacil and other antibacterial drugs, Tygacil should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria
- Appropriate specimens for bacteriological examination should be obtained to isolate and identify the causative organisms and determine their susceptibility to tigecycline